Harmony Biosciences Holdings, Inc. revenue
Harmony Biosciences Holdings, Inc.'s revenue was $868m in fiscal 2025, up 21.5% on the year before. Since fiscal 2019 ($6.0m) it has grown at a compound 129.2% a year. Over the last twelve months it was $960m.
Revenue history
| Fiscal year | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6 | 160 | 305 | 438 | 582 | 715 | 868 | 960 |
| Growth on the year before | — | +>999% | +91.2% | +43.4% | +32.9% | +22.8% | +21.5% | — |
| Gross profit | 4 | 132 | 250 | 354 | 461 | 558 | 670 | 724 |
| Gross margin | 73.7% | 82.6% | 81.8% | 80.9% | 79.2% | 78.1% | 77.2% | 75.4% |
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. | $960m | 24.3% | 24.4% |
| ANI Pharmaceuticals Inc | $978m | 30.9% | 34.6% |
| Axsome Therapeutics, Inc. | $865m | 54.2% | 57.0% |
| Supernus Pharmaceuticals, Inc. | $865m | 26.9% | 12.3% |
| Prestige Consumer Healthcare Inc. | $1.10bn | -1.4% | -0.7% |
| Corcept Therapeutics Inc | $831m | 16.0% | 24.7% |
Compare with peers
- ANI Pharmaceuticals Inc revenue
- Axsome Therapeutics, Inc. revenue
- Supernus Pharmaceuticals, Inc. revenue
- Prestige Consumer Healthcare Inc. revenue
- Corcept Therapeutics Inc revenue
Head to head: ANIP vs HRMYAXSM vs HRMYHRMY vs SUPNHRMY vs PBH
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies